ES2087565T3 - Nanosol aplicable farmaceuticamente y procedimiento para su preparacion. - Google Patents

Nanosol aplicable farmaceuticamente y procedimiento para su preparacion.

Info

Publication number
ES2087565T3
ES2087565T3 ES92924547T ES92924547T ES2087565T3 ES 2087565 T3 ES2087565 T3 ES 2087565T3 ES 92924547 T ES92924547 T ES 92924547T ES 92924547 T ES92924547 T ES 92924547T ES 2087565 T3 ES2087565 T3 ES 2087565T3
Authority
ES
Spain
Prior art keywords
gelatin
charge
pct
particles
active substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92924547T
Other languages
English (en)
Inventor
Jens-Christian Wunderlich
Ursula Schick
Juergen Werry
Juergen Freidenreich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alfatec Pharma GmbH
Original Assignee
Alfatec Pharma GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27203166&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2087565(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE19914140178 external-priority patent/DE4140178C2/de
Priority claimed from DE19914140177 external-priority patent/DE4140177C2/de
Priority claimed from DE19914140195 external-priority patent/DE4140195C2/de
Application filed by Alfatec Pharma GmbH filed Critical Alfatec Pharma GmbH
Application granted granted Critical
Publication of ES2087565T3 publication Critical patent/ES2087565T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • G—PHYSICS
    • G03—PHOTOGRAPHY; CINEMATOGRAPHY; ANALOGOUS TECHNIQUES USING WAVES OTHER THAN OPTICAL WAVES; ELECTROGRAPHY; HOLOGRAPHY
    • G03C—PHOTOSENSITIVE MATERIALS FOR PHOTOGRAPHIC PURPOSES; PHOTOGRAPHIC PROCESSES, e.g. CINE, X-RAY, COLOUR, STEREO-PHOTOGRAPHIC PROCESSES; AUXILIARY PROCESSES IN PHOTOGRAPHY
    • G03C1/00—Photosensitive materials
    • G03C1/005—Silver halide emulsions; Preparation thereof; Physical treatment thereof; Incorporation of additives therein
    • G03C1/04—Silver halide emulsions; Preparation thereof; Physical treatment thereof; Incorporation of additives therein with macromolecular additives; with layer-forming substances
    • G03C1/047—Proteins, e.g. gelatine derivatives; Hydrolysis or extraction products of proteins
    • G03C2001/0471—Isoelectric point of gelatine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y10S977/775—Nanosized powder or flake, e.g. nanosized catalyst
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/797—Lipid particle
    • Y10S977/798—Lipid particle having internalized material
    • Y10S977/799—Containing biological material
    • Y10S977/801—Drug
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y10S977/907—Liposome
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Optics & Photonics (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

SE DESCRIBEN NANOSOLES Y PROCESO PARA SU PREPARACION PERMITIENDO SOLUCIONES DISPERSAS COLOIDALMENTE DE SUSTANCIAS ACTIVAS ESCASAMENTE SOLUBLES EN AGUA PARA SER ESTABILIZADOS CON GELATINA O SUS DERIVADOS, MEDIANTE EL AJUSTE PARCIAL O COMPLETO DEL PUNTO ISO-IONICO (IIP, EQUIVALENTE A LA CARGA NEUTRA) ENTRE LA GELATINA Y LA SUPERFICIE CARGADA DE PARTICULAS DE SUSTANCIA ACTIVA. PARA NEUTRALIZAR LA CARGA DEL SISTEMA COMPUESTO DE PARTICULAS DE SUSTANCIA ACTIVA Y GELATINA, LA CARGA DE SUPERFICIE DE LAS PARTICULAS ESTA COMPENSADA MEDIANTE UNA CARGA OPUESTA CORRESPONDIENTE DE MOLECULAS DE GELATINA. POR ESTE MOTIVO, SE AJUSTA UNA CARGA DETERMINADA AL PUNTO ISOELECTRICO (IEP) Y EL VALOR DE PH DE LA SOLUCION SE FIJA SOBRE LAS MOLECULAS DE GELATINA. MEDIANTE LA ESTABILIZACION DE ESTA FORMA DEL ESTADO PRACTICAMENTE MONODISPERSO ASI GENERADO, SE REDUCE FUERTEMENTE LA MADURACION OSTWALD DE LAS PARTICULAS COLOIDALES DE LA SUSTANCIA ACTIVA ESCASAMENTE SOLUBLE. PUEDE SER OBTENIDA ASI UNA NUEVA FORMA DE ADMINISTRACION FARMACEUTICA DISPONIENDO DE NUEVAS PROPIEDADES CON COMPUESTOS ORGANICOS E INORGANICOS ESCASAMENTE SOLUBLES EN AGUA, EN PARTICULAR MEDICAMENTOS CON UNA BIODISPONIBILIDAD PROBLEMATICA. MEDICAMENTOS PREFERIDOS SON GLIBENCLAMIDA Y 3-DERIVADOS ACIDO INDOLILACETICO, TALES COMO INDOMETACINA O ACEMETACINA.
ES92924547T 1991-12-05 1992-12-04 Nanosol aplicable farmaceuticamente y procedimiento para su preparacion. Expired - Lifetime ES2087565T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19914140178 DE4140178C2 (de) 1991-12-05 1991-12-05 Akutform für ein Indolylessigsäurederivat enthaltendes Arzneimittel und seine Herstellung
DE19914140177 DE4140177C2 (de) 1991-12-05 1991-12-05 Nanosol-Akutform für Glibenclamid
DE19914140195 DE4140195C2 (de) 1991-12-05 1991-12-05 Pharmazeutisch applizierbares Nanosol und Verfahren zu seiner Herstellung

Publications (1)

Publication Number Publication Date
ES2087565T3 true ES2087565T3 (es) 1996-07-16

Family

ID=27203166

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92924547T Expired - Lifetime ES2087565T3 (es) 1991-12-05 1992-12-04 Nanosol aplicable farmaceuticamente y procedimiento para su preparacion.

Country Status (10)

Country Link
US (1) US5932245A (es)
EP (1) EP0615445B1 (es)
AT (1) ATE137962T1 (es)
AU (1) AU671965B2 (es)
CA (1) CA2125282C (es)
DE (1) DE59206324D1 (es)
DK (1) DK0615445T3 (es)
ES (1) ES2087565T3 (es)
GR (1) GR3020248T3 (es)
WO (1) WO1993010768A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3010160B1 (ja) * 1998-10-28 2000-02-14 株式会社ニッピ コラーゲン配合化粧品
US7708989B2 (en) * 1999-10-29 2010-05-04 Nitromed, Inc. Methods of treating vascular diseases characterized by nitric oxide insufficiency
US20010036479A1 (en) 2000-01-14 2001-11-01 Gillian Cave Glyburide composition
US7105176B2 (en) 2000-11-29 2006-09-12 Basf Aktiengesellschaft Production of solid preparations of water-soluble, sparingly water-soluble or water-insoluble active compounds
ES2282181T3 (es) * 2000-11-29 2007-10-16 Basf Aktiengesellschaft Procedimiento para la obtemncion de preparaciones solidas de productos activos solubles en agua, dificilmente solubles en agua o insolubles en agua.
DE10114178A1 (de) * 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
IL160103A0 (en) * 2001-08-06 2004-06-20 Astrazeneca Ab Aqueous dispersion comprising stable nanoparticles of a water-insoluble active substance and an excipient like middle chain triglycerides (mct)
DE10205362A1 (de) * 2002-02-08 2003-08-21 Abbott Gmbh & Co Kg Verfahren zur Herstellung wasserdispergierbarer Trockenpulver von in Wasser schwer löslichen Verbindungen
US7923029B2 (en) * 2002-04-11 2011-04-12 Medimmune Llc Spray freeze dry of compositions for pulmonary administration
GB0216700D0 (en) * 2002-07-18 2002-08-28 Astrazeneca Ab Process
ATE487470T1 (de) * 2002-09-11 2010-11-15 Elan Pharma Int Ltd Gel-stabilisierte wirkstoff-zusammensetzungen in nanoteilchengrösse
US6841179B2 (en) * 2002-11-14 2005-01-11 The Meow Mix Company Pet food compositions comprising electrostatically charged gelatin
GB0230088D0 (en) * 2002-12-24 2003-01-29 Astrazeneca Ab Therapeutic agents
GB0230087D0 (en) * 2002-12-24 2003-01-29 Astrazeneca Ab Therapeutic agents
GB0302673D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
GB0302672D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
GB0302671D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
WO2004089401A1 (ja) * 2003-04-01 2004-10-21 Yasuhiko Tabata 虚血治療剤
CA2527033A1 (en) * 2003-06-18 2004-12-23 Astrazeneca Ab 2-substitued 5,6-diaryl-pyrazine derivatives as cb1 modulators
GB0314057D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314261D0 (en) * 2003-06-19 2003-07-23 Astrazeneca Ab Therapeutic agents
DE102004041340A1 (de) * 2004-08-20 2006-02-23 Deutsche Gelatine-Fabriken Stoess Ag Nanopartikel und Verfahren zu deren Herstellung
CN101237850A (zh) * 2005-08-02 2008-08-06 德罗萨帕尔姆股份公司 含有吲哚美辛和/或阿西美辛的药物组合物
EP1912621B1 (de) * 2005-08-02 2019-09-11 Drossapharm AG Pharmazeutische zusammensetzung enthaltend indometacin und/oder acemetacin
CA2716872C (en) 2008-02-29 2015-02-10 Ferrosan Medical Devices A/S Device for promotion of hemostasis and/or wound healing
US9775819B2 (en) * 2009-09-16 2017-10-03 R.P. Scherer Technologies, Llc Oral solid dosage form containing nanoparticles and process of formulating the same using fish gelatin
GB201006218D0 (en) * 2010-04-14 2010-06-02 Ayanda As Composition
EP2540287A1 (en) 2011-07-01 2013-01-02 FutureChemistry Continuous flow production of gelatin nanoparticles
DE102011052396A1 (de) * 2011-08-04 2013-02-07 Gelita Ag Verfahren zur Herstellung einer stabilen Dispersion von Nanopartikeln, hergestellte Dispersion und deren Verwendung
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US8633178B2 (en) 2011-11-23 2014-01-21 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
CN104159527B (zh) 2012-03-06 2017-04-12 弗罗桑医疗设备公司 包含止血糊剂的压力容器
RU2636240C2 (ru) 2012-06-12 2017-11-21 Ферросан Медикал Дивайсиз А/С Сухая гемостатическая композиция
US8313774B1 (en) 2012-06-26 2012-11-20 Magnifica Inc. Oral solid composition
US9180091B2 (en) * 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
JP6390873B2 (ja) 2013-06-21 2018-09-19 フェッローサン メディカル ディバイス エー／エス 減圧膨張させた乾燥組成物およびそれを保持するためのシリンジ
BR112016013322B1 (pt) 2013-12-11 2020-07-21 Ferrosan Medical Devices A/S métodos para preparação de uma composição seca e para reconstituir uma composição seca, composição seca, uso de uma composição seca, e, kit
BR112017007466B1 (pt) 2014-10-13 2021-03-02 Ferrosan Medical Devices A/S método para preparar uma composição seca, método para reconstituir a composição seca, pasta, composição seca, recipiente, kit homeostático, e, uso de uma composição seca
RU2705905C2 (ru) 2014-12-24 2019-11-12 Ферросан Медикал Дивайсиз А/С Шприц для удерживания и смешивания первого и второго веществ
CA2986981A1 (en) 2015-07-03 2017-01-12 Ferrosan Medical Devices A/S Syringe for mixing two components and for retaining a vacuum in a storage condition
CN110944640A (zh) * 2017-06-20 2020-03-31 西雅图咖米公司 果胶胶粘组合物及其制造和使用方法
EP4321182A3 (en) 2018-05-09 2024-05-29 Ferrosan Medical Devices A/S Method for preparing a haemostatic composition

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB887901A (es) * 1960-04-13 1900-01-01
WO1985005029A1 (en) * 1984-05-09 1985-11-21 Medaphore Inc. Oral insulin and a method of making the same
NL194638C (nl) * 1986-12-19 2002-10-04 Novartis Ag Hydrosol die vaste deeltjes van een farmaceutisch actieve stof bevat en farmaceutisch preparaat dat deze hydrosol bevat.
FR2634397B2 (fr) * 1986-12-31 1991-04-19 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une proteine sous forme de nanoparticules
FR2608988B1 (fr) * 1986-12-31 1991-01-11 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanoparticules
CA1324083C (en) * 1987-03-09 1993-11-09 Tetsu Miyoshi Pharmaceutical preparations containing non-steroidal anti-inflammatory agents
ES2054052T3 (es) * 1988-06-30 1994-08-01 Centre Nat Rech Scient Procedimiento de preparacion de sistemas coloidales dispersables de una proteina en forma de nanoparticulas.

Also Published As

Publication number Publication date
EP0615445B1 (de) 1996-05-15
ATE137962T1 (de) 1996-06-15
WO1993010768A1 (de) 1993-06-10
DE59206324D1 (de) 1996-06-20
CA2125282A1 (en) 1993-06-10
AU671965B2 (en) 1996-09-19
GR3020248T3 (en) 1996-09-30
EP0615445A1 (de) 1994-09-21
DK0615445T3 (da) 1996-06-03
US5932245A (en) 1999-08-03
AU3080292A (en) 1993-06-28
CA2125282C (en) 1999-08-31

Similar Documents

Publication Publication Date Title
ES2087565T3 (es) Nanosol aplicable farmaceuticamente y procedimiento para su preparacion.
Ohnishi et al. Calcium-induced phase separations in phosphatidylserine-phosphatidylcholine membranes
KR830005850A (ko) 경구 투여용, 특히 소아경구 투여용 마이크로 캡슐화 바캄피실린산 부가염의 현탁액
NO971986L (no) Fremgangsmåte for fremstilling av små partikler
DK0615440T3 (da) Lægemiddel indeholdende et 2-arylpropionsyrederivat i nanosolform og dets fremstilling
BR9701263A (pt) Processo para preparar suspensões de carotenóides ou retinóides finamente dispersas suspensão de carotenóide ou retinóide e uso da suspensão de carotenóide ou retinóide ou do pó de carotenóide ou retinóide finamente disperso
ATE181087T1 (de) Superporöse polysaccharidgele
NO982364D0 (no) FremgangsmÕte for fremstilling av morfologisk anhetlige mikrokapsler, samt mikrokapsler fremstilt ved fremgangsmÕten
ATE55243T1 (de) Lipidnanopellets als traegersystem fuer arzneimittel zur peroralen anwendung.
BR9909636A (pt) Processo para a preparação de uma formulação, e, formulação
DE69520021D1 (de) Präparat mit verzögerter Wirkstoffabgabe
ATE114755T1 (de) Kolloidale zusammensetzung und ihre nutzung in der papier- und pappeherstellung.
GB1467172A (en) Gas transport agents
AR240874A2 (es) Un metodo para preparacion de una composicion que contiene un agente biologicamente activo de leberacion prolongada
SE8002900L (sv) Blandade salter av essentiella eller semi-essen-tiella aminosyror och kvevefria analoger derav
GR3018064T3 (en) Aqueous phospholipid vesicle dispersion, process for its manufacture and use thereof.
KR860003249A (ko) 피록시캄 1수화물의 제조 방법
Luzzi et al. Effect of additives and formulation techniques on controlled release of drugs from microcapsules
DE59301120D1 (de) Zubereitung zur topischen anwendung.
GB1521691A (en) Oleoresin emulsions
KR890012960A (ko) 결정성 β-락탐 용매화물
TR199901044T2 (en) Endos�lfan-mikrokaps�l da��l�m�.
KR850000405A (ko) 항진균제의 제조방법
ATE195655T1 (de) Verfahren zur herstellung kolloidaler wässriger lösungen schwerlöslicher wirkstoffe und ein lipid dafür
JPS6422816A (en) Production of microcapsule

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 0615445

Country of ref document: ES